IQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $259.13.

A number of research analysts have commented on IQV shares. Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley dropped their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of the company. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the 3rd quarter valued at about $147,683,000. 1832 Asset Management L.P. raised its holdings in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of IQVIA during the second quarter worth approximately $70,610,000. Impax Asset Management Group plc grew its holdings in IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $217.01 on Tuesday. The company’s fifty day simple moving average is $231.00 and its 200-day simple moving average is $229.16. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 52 week low of $191.45 and a 52 week high of $261.73. The company has a market cap of $39.39 billion, a PE ratio of 28.48, a P/E/G ratio of 2.25 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.